Arrowhead Pharmaceuticals has been granted a patent for a double-stranded ribonucleic acid (dsRNA) molecule designed to inhibit the expression of the RRM2 gene. The invention includes a pharmaceutical composition and methods for treating diseases caused by RRM2 gene expression. GlobalData’s report on Arrowhead Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Arrowhead Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Arrowhead Pharmaceuticals, Targeted cancer therapy was a key innovation area identified from patents. Arrowhead Pharmaceuticals's grant share as of April 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Dsrna for inhibiting rrm2 gene expression

Source: United States Patent and Trademark Office (USPTO). Credit: Arrowhead Pharmaceuticals Inc

A recently granted patent (Publication Number: US11920134B2) discloses a double-stranded ribonucleic acid molecule designed to inhibit the expression of a ribonucleotide reductase M2 (RRM2) gene. The molecule consists of a sense strand and an antisense strand, each less than 30 nucleotides in length, with the antisense strand containing specific nucleotide sequences. Additionally, the molecule may include modified nucleotides such as 2'-O-methyl modified nucleotides, phosphorothioate groups, and other variations to enhance its efficacy.

Furthermore, the patent details various configurations of the double-stranded ribonucleic acid molecule, including different lengths of the sense and antisense strands, the presence of modified nucleotides in both strands, and the addition of a 3' overhang with specific characteristics. The patent also covers the conjugation of the molecule to a ligand for targeted delivery. Additionally, pharmaceutical compositions containing the double-stranded ribonucleic acid molecule and a pharmaceutically acceptable carrier are described, highlighting the potential applications of this technology in the development of novel therapeutic interventions.

To know more about GlobalData’s detailed insights on Arrowhead Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies